Acesso livre
Acesso livre

Alergia e Imunologia

Revisão | Dose de SARS-CoV-2, infecção e desfechos de doença para COVID-19.

18 Out, 2021 | 08:53h

SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review – Clinical Infectious Diseases

Conteúdo relacionado: Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19.

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Oito meses depois: pesquisadores comparam as respostas imunes elicitadas por 3 vacinas contra COVID-19.

18 Out, 2021 | 08:50h

Comunicado de imprensa: Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines – Beth Israel Deaconess Medical Center

Estudo original: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines – New England Journal of Medicine

 

Comentário no Twitter

 

Estudo avaliou diversos regimes heterólogos de vacinas contra o SARS-CoV-2; não há dados de eficácia, mas houve maior aumento na produção de anticorpos nos participantes 15 e 29 dias depois da dose de reforço com vacinas da Moderna e da Pfizer.

15 Out, 2021 | 16:49h

Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report – medRxiv

Comentário: Study: Mixing and Matching COVID-19 Booster Shots Is Effective, Safe – U.S. News

 

Comentário no Twitter

 

Uma cartilha sobre o que se sabe a respeito de misturar e combinar vacinas contra Covid.

13 Out, 2021 | 13:40h

A primer on what we know about mixing and matching Covid vaccines – STAT

Conteúdos relacionados:

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Dados de mundo real mostram reatogenicidade aumentada em adultos após vacinação heteróloga em comparação à homóloga contra COVID-19.

8 Out, 2021 | 12:25h

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England – Eurosurveillance

Conteúdos relacionados:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Revisão | Esofagite eosinofílica.

8 Out, 2021 | 11:06h

Eosinophilic Esophagitis: A Review – JAMA (gratuito por tempo limitado)

Conteúdo relacionado:

Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis

Clinical Guidelines for the Management of Eosinophilic Esophagitis

Eosinophilic Esophagitis: Review and Update

Editorial | Vacinação contra Covid-19: evidência de queda na imunidade é exagerada.

4 Out, 2021 | 10:29h

Covid-19 vaccination: evidence of waning immunity is overstated – The BMJ

Conteúdos relacionados:

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

Diretriz de prática clínica para eventos adversos relacionados a tratamentos imunológicos contra o câncer.

27 Set, 2021 | 12:32h

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events – Journal for ImunoTherapy of Cancer

Conteúdos relacionados:

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (várias fontes sobre o tema)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment (várias fontes sobre o tema)

Estudo randomizado de fase 1/2 | Segurança e imunogenicidade de vacina inativada contra COVID-19 (BBIBP-CorV) em crianças e adolescentes de 3 a 17 anos de idade.

27 Set, 2021 | 12:11h

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Conteúdo relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

Revisão sistemática | Características clínicas da síndrome inflamatória multissistêmica em adultos.

27 Set, 2021 | 12:08h

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review – JAMA Network Open

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.